Relugolix and Histrelin: Interaction Details
- Relugolix
- Orgovyx
- Histrelin
- Supprelin
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Relugolix and Histrelin interaction:
Histrelin
- Supprelin
We don't have a drug information page for Histrelin yet. Have a question about Histrelin? Ask a pharmacist, free →
What Happens When You Take Relugolix With Histrelin
What can happen when they are taken together (rated Major)
Increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When relugolix is given together with medications that prolong the , the effects on the QT interval are . The androgen deprivation produced by GnRH or can itself lengthen the QT interval.
In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte disturbances, as well as in those receiving drugs recognized to prolong the QT interval, weigh whether the advantages of androgen deprivation therapy such as relugolix outweigh the possible hazards.1 Where feasible, do not use relugolix concurrently with QT prolonging agents. Should be necessary, refrain from using drugs that produce electrolyte abnormalities (that is, or ),2 correct any electrolyte abnormalities, and consider periodic monitoring of ECGs and electrolytes.1
The Relugolix and Histrelin Interaction, Explained
Both relugolix (Orgovyx) and histrelin (Supprelin) work by lowering hormone levels, which is part of how they treat prostate cancer or other conditions. One side effect of this kind of hormone-lowering treatment is that it can slightly affect your heart's electrical rhythm, something called . When two drugs that can each do this are used together, the effect may add up.
This concern is mostly theoretical, so please don't panic. Keep taking both medicines as prescribed. Your care team can watch for this by checking your heart tracing () and your blood minerals when needed. If you ever feel fainting, dizziness, or a fluttering heartbeat, let them know.
Effect: . Both agents lower androgens (GnRH relugolix; GnRH histrelin), and androgen deprivation itself can prolong the , so combined use may be additive.
- Direction: Increased QT prolongation risk (PD interaction, not enzyme-based).
- Onset: Unspecified.
- Evidence: Theoretical.
- Severity: Major.
Management: Weigh benefit of ADT against risk in patients with congenital long QT, CHF, or electrolyte disturbances. Avoid where possible. If combined, avoid agents causing /, correct electrolytes, and consider periodic and electrolyte monitoring.
See the 3 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Relugolix and Histrelin Interact
The likely mechanism
How to Manage the Relugolix and Histrelin Interaction
Here is how a care team typically handles this combination:
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Your team will weigh the benefits of hormone therapy against your personal heart risk, especially if you have a history of long QT syndrome, heart failure, or low blood minerals.
- They may check periodic ECGs and electrolytes (potassium and magnesium) and correct any that are low.
- Tell your pharmacist or doctor about all other medicines you take, since some also affect QT.
Report any fainting, dizziness, or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Relugolix or Histrelin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes
In an investigation of male patients undergoing androgen deprivation therapy (ADT) using individual case safety reports from VigiBase, the international pharmacovigilance database, researchers identified 184 cases of acquired long-QT syndrome (aLQTS) and/or (TdP; 11% of which were fatal), along with 99 cases of sudden death linked to ADT. The majority of aLQTS/TdP cases (62%) and sudden death cases (88%) related to ADT arose without of other agents recognized to raise TdP risk; nevertheless, use of 1 drug and of 2 or more drugs carrying conditional, possible, or known TdP risk was reported in a portion of aLQTS/TdP (23% or 43%) and sudden death (18% and 22%) events.
The agents regarded as ADTs included abiraterone, gonadotropin-releasing hormone and , nonsteroidal androgen receptor indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism. Among the 10 ADTs assessed, 7 demonstrated a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride.
The patients had a median age of about 76 years, and the median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were primarily receiving ADT for prostate cancer, while some received it for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%); 17% were on ADT combination therapy.3
Relugolix and Histrelin: Common Questions
How serious is the Relugolix and Histrelin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Relugolix and Histrelin interaction managed?
Here is how a care team typically handles this combination: Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Your team will weigh the benefits of hormone therapy against your personal heart risk, especially if you have a history of long QT syndrome, heart failure, or low blood minerals. They may check periodic ECGs and electrolytes (potassium and magnesium) and co… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Relugolix and Histrelin Interaction
Ask in your own words about taking Relugolix and Histrelin together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Other Serious Interactions of Relugolix and Histrelin
Also serious with Relugolix
- DronedaroneContraindicated
- LevoketoconazoleContraindicated
- PimozideContraindicated
- RanolazineContraindicated
Also serious with Histrelin
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Relugolix
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 149 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.